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Abstract
BACKGROUND: Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening
infections. While reduction of chemotherapy dose or delay of the subsequent treatment cycle and,
consequently, reduction of relative dose intensity (RDI) may limit myelotoxicity, these actions can also
impact adversely on treatment outcome and should be avoided in adjuvant settings. PATIENTS AND
METHODS: Based on data from 444 breast cancer patients in the INC-EU Prospective Observational
European Neutropenia Study, we have evaluated patient-specific and treatment-specific factors that
impact on the incidence of grade 4 CIN (absolute neutrophil count <0.5 x 10(9)/L), either during the
first or in any cycle of (neo)adjuvant chemotherapy, across a range of regimens and doses. RESULTS:
Using multivariate logistic regression analysis, risk factors for grade 4 CIN were identified as older age,
lower weight, higher planned dose intensity of doxorubicin, epirubicin, or docetaxel, higher number of
planned cycles, vascular comorbidity, lower baseline white blood cell count, and higher baseline
bilirubin. Use of colony-stimulating factor before a neutropenic event occurred, dose delays, and dose
reductions were protective against grade 4 CIN. CONCLUSIONS: By identifying risk factors for grade
4 CIN, CSF prophylaxis may be appropriately targeted to prevent low RDI in patients treated with
curative intent.
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Summary  
Background 
Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While 
reduction of chemotherapy dose or delay of the subsequent treatment cycle, and consequently 
reduction of relative dose intensity (RDI), may limit myelotoxicity, these actions can also impact 
adversely on treatment outcome and should be avoided in adjuvant settings. 
Patients and Methods 
Based on data from 444 breast cancer patients in the INC-EU Prospective Observational European 
Neutropenia Study, we have evaluated patient- and treatment-specific factors that impact on the 
incidence of grade 4 CIN (absolute neutrophil count < 0.5 x 10
9
/L), either during the first or in any 
cycle of (neo)adjuvant chemotherapy, across a range of regimens and doses. 
Results 
Using multivariate logistic regression analysis, risk factors for grade 4 CIN were identified as older 
age, lower weight, higher planned dose intensity of doxorubicin, epirubicin or docetaxel, higher 
number of planned cycles, vascular comorbidity, lower baseline white blood cell count, and higher 
baseline bilirubin. Use of colony-stimulating factor before a neutropenic event occurred, dose delays, 
and dose reductions, were protective against grade 4 CIN.  
Conclusions 
By identifying risk factors for grade 4 CIN, CSF prophylaxis may be appropriately targeted to prevent 
low RDI in patients treated with curative intent. 
 
Keywords 
Neutropenia, chemotherapy, breast cancer, risk factors. 
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Introduction 
Breast cancer is the most common form of cancer amongst women in Europe, with an incidence of 
110 per 100,000 and mortality of 25 per 100,000 in 2006 
[1]
. Disease-free and overall survival rates 
have significantly improved in the last 30 years with the introduction of treatment with adjuvant 
chemotherapy in addition to surgery 
[2]
. However, the benefits of adjuvant chemotherapy are largely 
dependent on optimal dose delivery, without dose delays and reductions 
[3-5]
. In a 20 year follow-up 
study of women treated with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) for node-
positive breast cancer, receiving full dose chemotherapy (≥ 85%) impacted positively on disease-free 
survival (DFS) and overall survival (OS) 
[3]
. A more recent study of anthracycline-based non-taxane 
chemotherapy regimens similarly showed benefits in DFS and OS for patients receiving full dose and 
on-schedule chemotherapy (≥ 85%) [5]. The benefit of higher dose intensity for DFS and OS has also 
been demonstrated for adjuvant FAC (5-fluorouracil, doxorubicin, and cyclophosphamide) 
chemotherapy in the treatment of node-positive breast cancer 
[4]
.  
 
Chemotherapy frequently results in severe chemotherapy-induced neutropenia (grade 4 CIN; 
absolute neutrophil count [ANC] < 0.5 x 10
9
/L) and febrile neutropenia (FN; ANC < 0.5 x 10
9
/L and 
temperature ≥ 38°C). Myelosuppression puts patients at risk of life-threatening infection. In Europe, it 
is common practice in many hospitals to delay or reduce chemotherapy doses in an effort to minimise 
this risk, or in response to the occurrence of a myelosuppressive event or low neutrophil nadir. For 
example, Chirivella et al. reported that in their hospital it was standard protocol to delay chemotherapy 
by 5-7 days even at lower grades of neutropenia, if the neutrophil count was < 1.5 x 10
9
/L, or if the 
platelet count was < 100 x 10
9
/L 
[5]
.The NeuCuP (Neulasta [pegfilgrastim] versus Current Practice) 
integrated analysis also demonstrated the occurrence of dose delays in current practice 
[6]
. 
Consequently, patients receive reduced relative dose intensity (RDI) 
[7]
. We have previously reported 
that the practice of dose delays and reductions affects a high proportion of breast cancer patients; 
34% of patients in the INC-EU Prospective Observational European Neutropenia Study experienced 
grade 4 CIN, over 20% received a reduced RDI (≤ 85%), and grade 4 CIN was a significant predictor 
of low RDI, dose delays and dose reductions 
[8]
.  
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Colony-stimulating factor (CSF) primary prophylaxis can be used to support chemotherapy delivery by 
reducing the duration of severe neutropenia 
[9-12]
. Current European Organisation for Research and 
Treatment of Cancer (EORTC) guidelines recommend primary prophylaxis for patients where 
reductions in dose intensity have been shown to result in poorer prognosis, even where the overall FN 
risk is low 
[10]
.  
 
The aim of the present analysis was to evaluate factors that predict grade 4 CIN in early stage breast 
cancer patients treated with curative intent, a patient group for whom delivery of full RDI has been 
shown to benefit survival 
[3-5]
. By identifying risk factors, protective measures may be targeted towards 
patients most at risk of developing neutropenia and subsequent chemotherapy dose delays and 
reductions. 
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Materials and Methods 
Study design and patient selection 
The study design and patient selection have previously been described in detail 
[8]
. Briefly, the INC-
EU Prospective Observational European Neutropenia Study involved 749 patients with histologically 
confirmed breast cancer, non-Hodgkin lymphoma or Hodgkin lymphoma, enrolled at 66 centres in 
Belgium, France, Germany, Spain, and the UK between January 2004 and May 2005. Ethical 
approval was obtained from all participating centres, and all patients provided informed consent. The 
present analysis covers a subset of 444 breast cancer patients. Patients eligible for inclusion required 
adjuvant or neoadjuvant chemotherapy for grade I-III breast cancer, with at least four cycles of a 
myelosuppressive chemotherapy regimen sequence planned. Permitted chemotherapy regimens 
included anthracycline-containing regimens including AC (doxorubicin and cyclophosphamide), EC 
(epirubicin and cyclophosphamide), FAC (5 fluorouracil, doxorubicin, and cyclophosphamide), FEC 
(5-fluorouracil, epirubicin, and cyclophosphamide), and E-CMF (epirubicin, cyclophosphamide, 
methotrexate, and 5-fluorouracil); taxane-containing or sequential regimens including TAC (docetaxel, 
doxorubicin, and cyclophosphamide); and CMF. 
 
Statistical methods 
From an initial set of covariates considered to be potential predictors of grade 4 CIN (ANC < 0.5 x 
10
9
/L), based on biomedical/clinical reasoning and given earlier published reports, candidate model 
covariates were pre-selected on the basis of statistical criteria (presence of an association with p ≤ 
0.25 in standard univariate analysis) and clinical relevance. Subsequently, multivariate logistic 
regression models of grade 4 CIN occurrence in any cycle and in cycle 1 were developed. Main 
effects were identified through manual exploration of all plausible combinations of candidate 
covariates. Generalised estimation equations-based robust standard error estimates were used to 
allow for clustering by study centre. For candidate predictors with more than 5% missing values, 
missing categories were introduced in order to avoid loss of observations. Sensitivity analyses were 
performed to address concerns that this approach can lead to biased estimation results 
[13,14]
. 
 
Model fit was assessed using the Hosmer-Lemeshow goodness of fit test and plots of mean observed 
versus mean predicted event probabilities, by deciles of the linear predictor. Predictive ability of the 
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models was characterised by sensitivity and specificity, positive and negative predictive value (PPV 
and NPV), the area under the receiver operating characteristic (ROC) curve, and the total proportion 
of correct predictions. The ability of the models to predict lower grades of CIN ≥ 3 (ANC < 1.0 x 109/L), 
or ≥ 2 (ANC < 1.5 x 109/L), was also tentatively determined. Ten-fold cross-validation was performed 
in the absence of an independent validation dataset. Finally, clinical utility of the ‘any cycle’ model 
was assessed by applying the model to hypothetical case scenarios. 
 
The initial set of potential predictors of grade 4 CIN in any cycle included patient factors, baseline 
laboratory measures and comorbidities, frequency of haematology laboratory tests, planned treatment 
characteristics, and actual treatment characteristics before a grade 4 CIN occurred. For the model of 
grade 4 CIN occurrence in cycle 1 of chemotherapy, an appropriate subset of these covariates was 
considered. 
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Results 
Patient and treatment characteristics 
Patient and baseline disease characteristics are shown in Table 1. The majority of patients (70%) 
received anthracycline-based treatments; remaining patients received anthracycline- and taxane-
containing sequential regimens (20%), TAC (4%), other taxane-containing regimens (2%) or CMF 
(4%). Patients receiving non-sequential chemotherapy regimens were planned for 4 cycles (25%) or 6 
cycles (72%) in the vast majority of cases. Patients receiving sequential regimens were typically 
planned for 6 cycles (10%) or 8 cycles (89%). Cycles were three weeks long in most cases. Primary 
CSF prophylaxis was provided to 9% of patients overall (5% for anthracycline-based regimens, 14% 
for anthracycline- and taxane-containing regimens, 71% for TAC and 11% for CMF), and secondary 
CSF prophylaxis or treatment was provided to a further 24% of patients. 
 
Incidence of CIN 
Overall, grade 4 CIN occurred in around a third of patients (152/442; 34%) at some stage during their 
treatment (Table 2), and was most frequent in patients receiving TAC chemotherapy (7/17; 44%). 
Over two thirds of all grade 4 CIN events (107/152; 70%) occurred during the first cycle of treatment, 
and almost one in four breast cancer patients (107/442; 24%) experienced first cycle grade 4 CIN. 
Lower grades of CIN were also frequent. Across all cycles, maximum CIN grades of 3, 2 and 1 were 
seen in 132 (30%), 72 (16%) and 67 (15%) of 442 patients, respectively. Only 19 patients (4%) 
experienced no CIN. 
 
Chemotherapy dose limitations 
Patients were more likely to receive a reduced RDI (≤ 85%) if they experienced grade 4 CIN, whether 
in the first cycle of chemotherapy or at any other point during treatment (Table 3). In patients without 
grade 4 CIN, the risk of RDI ≤ 85% was 17% (95% confidence interval [CI], 13-22%), whereas in 
patients with grade 4 CIN in any cycle, the risk of RDI ≤ 85% was 28% (95% CI, 21-36%). The 
occurrence of grade 4 CIN in any cycle of chemotherapy was also significantly associated with dose 
delays (≥ 4 days; odds ratio [OR] 1.57, 95% CI, 1.02-2.40) and dose reductions (≥ 10% of planned 
dose; OR 1.86, 95% CI, 1.16-2.97).  
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Predictors of CIN 
Significant risk factors associated with the occurrence of grade 4 CIN in any cycle of chemotherapy 
were identified using logistic regression analysis (Table 4). These were older age, lower weight, 
higher planned dose intensity of doxorubicin, epirubicin or docetaxel, higher number of planned 
cycles, vascular comorbidity, lower baseline WBC count, and higher baseline bilirubin. A higher 
number of haematology laboratory tests per cycle, and availability of a cycle 1 nadir haematology 
laboratory test, were also shown to be significant in the model, but this may be related to patient 
management and not a direct correlation between these tests and CIN. The model also identified 
factors that protected against grade 4 CIN; these were CSF use, dose reductions and dose delays, all 
before an event occurred. 
 
We investigated whether weight may have been identified as a predictor of grade 4 CIN because 
body-surface area (BSA)-based chemotherapy dosing leads to higher chemotherapy dose per 
kilogram of body weight in lighter patients. Consistent with this hypothesis, substantial and highly 
significant negative correlations between BSA and dose per kilogram bodyweight were found for a 
wide range of anti-malignant substances. For example, the correlation between BSA and absolute 
doxorubicin dose per kilogram bodyweight in the first cycle of chemotherapy was -0.76 for TAC (N = 
88; p < 0.001) and -0.81 for AC chemotherapy (N = 17; p < 0.001, Fig 1). 
 
The model correctly classified 320 of 434 patients (73%). The area under the ROC curve was 0.82 
(95% CI, 0.78-0.86) and test characteristics (using the cut-off with the best ability to discriminate 
between occurrence and non-occurrence of grade 4 CIN) were sensitivity 73%, specificity 74%, PPV 
59%, and NPV 84%. Under 10-fold cross-validation conditions the area under the ROC curve was 
0.78 (95% CI, 0.63-0.93), demonstrating that predictive ability was only modestly decreased. 
 
Risk factors for the occurrence of grade 4 CIN in the first cycle of chemotherapy were also modelled 
by logistic regression. Factors associated with a significant risk of, or protection against, grade 4 CIN 
were broadly consistent with the ‘any cycle’ model with the exception of high baseline bilirubin, low 
baseline white blood cell (WBC) count and age, which showed consistent direction of effects, but only 
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reached statistical significance in the ‘any cycle’ model. The area under the ROC curve for the ‘cycle 
1’ model was 0.73 (95% CI, 0.68-0.78). The PPV was 38% and the NPV was 86%. 
 
When the ‘any cycle’ model was tentatively used to predict CIN grades of 3 or higher, the area under 
the ROC curve was 0.71 (95% CI, 0.66-0.76), and PPV and NPV were 77% and 51%, respectively. 
Prediction for the first cycle yielded an area under the ROC curve of 0.71 (95% CI, 0.66-0.75). PPV 
was 62% and NPV was 64%. For CIN grades of 2 or higher, ROC results were similar, but the shift of 
predictive ability towards higher PPV and lower NPV was stronger, given that 83% of patients 
experienced this endpoint. 
 
Patient scenarios 
Table 5 shows the predicted risk of grade 4 CIN during any cycle of chemotherapy for a selection of 
hypothetical patients presenting various risk factors. Hypothetical subjects of either 70 kg (the median 
weight of the breast cancer study population) or 55 kg received chemotherapy with either FEC-T 
(FEC followed by docetaxel) or TAC. This table of predicted risk is based on the assumption that no 
CSF support was given. Lower weight increased the risk of grade 4 CIN at any age and for both types 
of chemotherapy regimen, and the highest risk was in subjects with multiple risk factors.
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Discussion 
In this sample of breast cancer patients receiving chemotherapy treatment, multivariate analyses 
were used to identify risk factors for grade 4 neutropenia. Patient characteristics contributing to 
increased risk were higher age and lower weight, vascular comorbidity and levels of some baseline 
laboratory measures, specifically low baseline WBC count and high baseline bilirubin. Treatment 
factors that increased risk of grade 4 CIN were high planned chemotherapy dose intensity and a 
higher number of planned chemotherapy cycles, and a higher number of haematology laboratory tests 
measured per cycle. CSF use, dose reductions or dose delays, all before a neutropenic event 
occurred, protected against grade 4 CIN.  
 
The relationship between increased risk of myelotoxicity and older age is well established and is 
incorporated in both European and American clinical practice guidelines 
[10-12]
. Lower weight may 
increase the risk of grade 4 CIN as a result of drug dosing by BSA; as lighter patients are exposed to 
more chemotherapy per kilogram of bodyweight this may result in higher toxicity. In our sample this 
assumption was supported by significant correlations observed between dose per kilogram of each 
chemotherapy agent and BSA.  
 
In our model, a strong predictor for grade 4 CIN was high baseline bilirubin, which is indicative of 
impaired liver function 
[15]
. Baseline bilirubin level may be a particularly important predictive factor in 
patients receiving chemotherapy with doxorubicin, epirubicin or docetaxel, as these agents are 
detoxified by the liver rather than excreted by the kidneys 
[16]
. Baseline laboratory measures of pre-
treatment ANC and WBC count have been shown to predict neutropenic events in breast cancer 
patients receiving FEC chemotherapy 
[17]
; consistent with the present finding that low baseline WBC 
was a risk factor for grade 4 CIN. From our dataset, we could not confirm an independent role of 
lymphocyte count, which has been reported by some authors 
[17-19]
. 
 
High planned chemotherapy dose intensity of doxorubicin, epirubicin or docetaxel was a risk factor for 
grade 4 CIN. Using planned chemotherapy dose intensity as a measure of the myelosuppressive 
potential of a regimen allows comparison between different regimens, and between a range of 
planned drug doses within the same regimen (for example, in this study, epirubicin doses in FEC 
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regimens ranged from 50-120 mg/m
2 BSA). As the model was derived from data that reflect the ‘real 
life’ clinical situation of dose variation, it can potentially be used in clinical practice to predict grade 4 
CIN in breast cancer patients across a variety of regimens and doses. It should be noted, however, 
that correlations with the use of other anti-malignant agents may have masked the contribution of 
those agents to the neutropenic potential of the chemotherapy regimens studied. Validation against 
an independent data set is pending. 
 
The average number of haematology laboratory tests per cycle at each study site (averaged across 
patients) and the presence of a nadir haematology laboratory test in cycle 1 were significant predictive 
factors for grade 4 CIN. The most probable explanation for this is that grade 4 CIN is more likely to be 
detected at sites which tend to perform more haematology laboratory tests. This observation raises 
the possibility that neutropenic events may be under-reported. 
 
Consistent with current literature, CSF prophylaxis was strongly protective against grade 4 CIN 
[10,12,20]
. Dose reductions and dose delays before an event occurred were also identified as protective 
factors against grade 4 CIN; although they may be an appropriate course of action to limit neutropenia 
in patients receiving palliative treatment, in an adjuvant setting reductions in chemotherapy dose 
intensity have been shown to impact negatively on treatment outcome 
[2-5]
. Current EORTC and 
American Society of Clinical Oncology guidelines recommend CSF use to support dose dense or 
dose intense regimens that have survival benefits, where reductions in intensity or density are known 
to be associated with a poor prognosis, or where a regimen ± risk factors, is associated with a > 20% 
risk of FN 
[10,12]
.  
 
A recent model identified risk factors for FN or grade 4 neutropenia across multiple chemotherapy 
cycles in early stage breast cancer patients in the US that were broadly similar to those identified in 
our analysis 
[21]
. The planned intensity of different chemotherapy regimens impacted on the risk of 
neutropenia in both models; in the US model TAC regimens were associated with the highest 
neutropenia risk, consistent with the identification of planned dose intensity of doxorubicin, epirubicin 
or docetaxel as predictors in the present model. Baseline bilirubin was a risk factor for neutropenic 
events in both models, as was baseline WBC. Lower glomerular filtration rate, predictive of 
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neutropenic events in the US model, was a replacement for age. CSF use was protective against 
neutropenia in both analyses.  
 
Risk and protective factors we identified for grade 4 CIN in any cycle of chemotherapy were also 
identified in a model for the first cycle of chemotherapy. Effect sizes were comparable, although some 
covariates were no longer statistically significant, presumably due to the lower number of events in 
the first cycle analysis. The only substantial reduction in effect size was seen in baseline bilirubin. It is 
possible that after one cycle of chemotherapy liver function was not sufficiently impaired to affect 
chemotherapy drug metabolism, but with repeated exposure to chemotherapy agents this impairment 
could have become more pronounced. 
 
Our model showed good predictive ability, correctly classifying 73% of grade 4 CIN patients, and with 
an NPV of 84%. Some predictive ability was maintained when the endpoint was modified to include 
lower CIN grades. The role of individual, intrinsic chemosensitivity, which we cannot adequately 
predict to date, may make it difficult to achieve better test characteristics in neutropenia risk models 
[17]
. The model performed well in ten-fold cross-validation but remains to be validated further against 
an independent data set.  
 
To evaluate its potential clinical utility, the model was applied to scenarios of hypothetical patients 
treated with FEC-T, representative of a taxane-anthracycline sequential therapy, which has been 
demonstrated to be efficacious in treatment of breast cancer 
[22]
, and TAC, representative of a more 
myelotoxic regimen 
[10]
. Older and lower weight patients were shown to have a higher predicted risk of 
grade 4 CIN, independent of other risk factors. The highest risk of neutropenia was in patients with 
multiple risk factors. 
 
The identification of risk factors for grade 4 CIN has important clinical implications. Current guidelines 
recommend CSF use not only when the overall risk of FN is > 20%, but also to allow maintenance of 
chemotherapy dose. Few patients in this dataset experienced FN; however grade 4 CIN was frequent 
and was associated with chemotherapy dose delays, reductions, and low RDI. A higher proportion of 
patients who had grade 4 CIN received low RDI, compared to patients without grade 4 CIN. The issue 
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of impaired RDI achievement in routine practice deserves greater attention. When the 20 year 
outcome results from the Bonadonna study 
[3]
 are applied in different breast cancer populations, the 
findings are similar; namely a lower than planned dose intensity is associated with inferior long term 
disease-free and overall survival 
[23]
. 
 
In conclusion, we have identified several risk factors for grade 4 CIN in breast cancer patients 
receiving adjuvant chemotherapy in European practice. Our model provides a broad list of risk factors 
applicable across a range of chemotherapy regimens. Such risk factors may be considered by 
clinicians identifying patients vulnerable to dose reductions and delays, which may ultimately 
compromise chemotherapy delivery, to enable appropriate targeting of supportive care. 
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Table 1: Patient and baseline disease characteristics 
Characteristic (n = 444)  
Age (years), mean ± SD (range) 53.5 ± 10.2 (27–81) 
Female gender, n (%) 441 (99.3) 
Weight (kg), mean ± SD (range)
a
 71.5 ± 14.2 (41–138) 
BSA (m
2
), mean ± SD (range) 1.8 ± 0.2 (1.3-2.3) 
HER2/Neu status, n (%)
b
 
  0 
  1+ 
  2+ 
  3+ 
 
199 (53.1) 
54 (14.4) 
40 (10.7) 
82 (21.9) 
Disease stage at inclusion, n (%)
c
 
  I 
  II 
  III 
 
109 (24.9) 
241 (55.0) 
88 (20.1) 
No. of baseline comorbidities, mean ± SD (range) 1.6 ± 2.1 (0–11) 
Vascular comorbidity, n (%)
d
 87 (19.6) 
Baseline WBC < 5 x 10
9
/L, n (%) 59 (13.4) 
Baseline bilirubin > 17.1 μmol/L (1.0 mg/dL), n (%) 17 (4.0) 
 
BSA – body surface area; SD – standard deviation; WBC – white blood cell count. 
 
a
n = 441 due to missing values. 
b
n = 375 due to missing values. 
c
n = 438 due to missing values. 
d
Most of these patients had hypertension. 
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Table 2: Occurrence of grade 4 chemotherapy-induced neutropenia by regimen type 
Regimen group
a
 n
b
  
Any cycle grade 4 CIN 
%
 
(n) 
First cycle grade 4 CIN 
%
 
(n) 
Total 444  34.4 (152) 24.4 (107) 
Anthracycline-based
 
312  36.7 (114) 28.5 (88) 
Sequential anthracycline- and taxane-
containing  
87  32.2 (28) 16.5 (14) 
TAC 17 43.8 (7) 18.8 (3) 
Other taxane-containing 10 22.2 (2) 22.2 (2) 
CMF 18 5.6 (1) 0 (0) 
 
CIN – chemotherapy-induced neutropenia; CMF - cyclophosphamide, methotrexate, and 5-fluorouracil; TAC - Taxotere 
(docetaxel) Adriamycin (doxorubicin), and cyclophosphamide. 
 
a
Detailed information regarding treatment regimens has been reported elsewhere [8].  
b
Denominator values for calculations are the regimen n-values in column 2, except as follows: Any cycle grade 4 CIN; total (N = 
442), anthracycline-based (N = 311), TAC (N = 16); First cycle grade 4 CIN; total (N = 438), anthracycline-based (N = 309), 
sequential anthracycline- and taxane-containing (N = 85), TAC (N = 16), other taxane-containing (N = 9) due to missing values. 
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Table 3: Grade 4 chemotherapy-induced neutropenia and impaired chemotherapy  
Type of dose limitation Any grade 4 CIN Grade 4 CIN in cycle 1 
Delays
a
 OR (95% CI) 1.57 
(1.02-2.40) 
1.23 
(0.76-1.97) 
Reductions
b
, corrected
c 
OR (95% CI) 1.86 
(1.16-2.97) 
1.64 
(0.98-2.73) 
RDI ≤ 85% OR (95% CI) 1.89 
(1.15-3.10) 
1.92 
(1.13-3.26) 
 
CIN – chemotherapy-induced neutropenia; CI – confidence interval; FN – febrile neutropenia; OR – odds ratio [Bold OR values 
indicate p < 0.05]; RDI – relative dose intensity. 
 
a
In at least one cycle; ≥ 4 days 
b
In at least one anti-malignant drug and at least one cycle; ≥ 10% of planned dose. 
c
Taking into account non-administered cycles. 
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Table 4: Logistic regression model for predicting occurrence of grade 4 chemotherapy-
induced neutropenia in any cycle of chemotherapy
* 
Variable Odds ratio 95% CI p value 
Age (per additional 10 years) 1.35 1.06 1.73 0.016 
Weight (per additional 10 kg) 0.67 0.57 0.79 0.000 
Planned doxorubicin dose intensity
a
 1.17 1.07 1.28 0.001 
Planned epirubicin dose intensity
a
 1.14 1.08 1.19 0.000 
Planned docetaxel dose intensity
a
 1.06 1.02 1.11 0.006 
Planned number of cycles (per additional cycle) 1.65 1.27 2.14 0.000 
Vascular comorbidity (present vs. absent) 2.29 1.25 4.20 0.007 
Baseline WBC count (x 10
9
/L) 0.87 0.76 0.99 0.037 
Baseline bilirubin > 17.1 μmol/L  
(1.0 mg/dL) 
4.38 1.25 15.33 0.021 
Baseline bilirubin missing
b
 2.62 0.78 8.78 0.118 
Dose reductions before an event occurred (≥ 10% 
of planned dose) 
0.21 0.05 0.99 0.049 
Dose delays before an event occurred (≥ 4 days) 0.20 0.10 0.39 0.000 
Cycle 1 nadir haematology lab unavailable 0.11 0.02 0.53 0.006 
Haematology labs per cycle
c
 2.44 1.23 4.86 0.011 
CSF before an event occurred
d
 0.36 0.18 0.70 0.003 
 
CI - confidence interval; CIN – chemotherapy-induced neutropenia; CSF – colony-stimulating factor; WBC – white blood cell 
count. 
 
*
Number of observations = 434, Wald chi
2
 = 160.69, p > chi-squared = 0.000, Log pseudolikelihood = -209.49. 
 
a
Per additional mg/m
2
 body surface area/week. 
b
Missing category introduced to avoid loss of observations. 
c
Site-level average number of haematology laboratory tests per cycle (after cycle 1 and before a grade 4 CIN occurred; 
excluding start of cycle laboratory tests). 
d
Myelopoietic growth factor use before a grade 4 CIN occurred. 
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Table 5: Predicted risk of grade 4 chemotherapy-induced neutropenia in any cycle of chemotherapy for breast cancer, in the absence of CSF support, 
according to age, weight, and presence of risk factors.  
 
55 kg* 70 kg* 
Risk factors 35 years 50 years 65 years 35 years 50 years 65 years 
FEC-T chemotherapy
a
       
None 37% 48% 59% 24% 34% 45% 
WBC low
b
  46% 58% 68% 32% 43% 54% 
Vascular comorbidity 57% 68% 77% 43% 54% 65% 
Baseline bilirubin high
c 
72% 80% 86% 59% 69% 78% 
WBC low
b
 + vascular comorbidity + bilirubin high 90% 93% 96% 83% 88% 92% 
High number of haematology labs per cycle
d
 48% 59% 69% 34% 44% 56% 
TAC chemotherapy
e
       
None 61% 71% 80% 46% 58% 68% 
WBC low
b
  70% 78% 85% 56% 67% 76% 
Vascular comorbidity 78% 85% 90% 66% 76% 83% 
Baseline bilirubin high
c 
87% 92% 94% 79% 86% 90% 
WBC low
b
 + vascular comorbidity + bilirubin high 96% 97% 98% 93% 95% 97% 
High number of haematology labs per cycle
d
 71% 79% 86% 57% 68% 77% 
 
BSA – body surface area; CIN – chemotherapy-induced neutropenia; CSF – colony-stimulating factor; WBC – white blood cell count. 
 
*The median weight of the breast cancer study population was 70 kg, and 55 kg was chosen to represent a low weight patient. It was assumed that the cycle 1 nadir haematology laboratory test was 
available, that there were no dose delays or dose reductions before an event occurred, and that no CSF was administered before an event occurred.  
 
a
Standard FEC–T, i.e. 3 cycles of FEC with epirubicin 100 mg/m
2
 BSA followed by 3 cycles of docetaxel 100 mg/m
2
 BSA; cycle length 3 weeks  
b
Baseline WBC 4.0 x 10
9
/L instead of 6.7 x 10
9
/L 
cBaseline bilirubin > 17.1 μmol/L (1.0 mg/dL) 
d
1.0 instead of 0.5 site-level average no. of haematology laboratory tests per cycle (after cycle 1 and before a grade 4 CIN occurred; excluding start of cycle laboratory tests). 
e
Standard TAC, i.e. 6 cycles of TAC with doxorubicin 50 mg/m
2
 BSA and docetaxel 75 mg/m
2
 BSA; cycle length 3 weeks 
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Fig. 1 Scatterplot of absolute doxorubicin dose per kg bodyweight in the first cycle of 
chemotherapy and body surface area at baseline 
 
 
AC - Adriamycin (doxorubicin) 60 mg/m
2
; cyclophosphamide 600 mg/m
2
 
TAC - Taxotere (docetaxel) 75 mg/m
2
, doxorubicin 50 mg/m
2
, and cyclophosphamide 500 mg/m
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